In a significant step, two more Central Drug Laboratories have been readied at Pune and Hyderabad for Covid vaccine testing. The step has been taken in the wake of the Covid-19 pandemic, and considering the enhanced production of Covid vaccines in the country.
Currently, India has a Central Drugs Laboratory (CDL) at Kasauli, which is the National Control Laboratory for testing and pre-release certification of immunobiologicals (vaccines and antisera) meant for human use in India.
According to a Science & Technology Ministry statement, the facility at the National Centre for Cell Science, Pune, has now been notified as a Central Drugs Laboratory for testing and lot release of Covid-19 vaccines, through a gazette notification issued by the Health & Family Welfare Ministry on June 28.
The facility at the National Institute of Animal Biotechnology, Hyderabad is likely to receive necessary notification shortly, it said.
"With generous support from PM CARES Fund trust in a very short span of time, both the institutions, through relentless efforts, have set up the state-of-the-art modern facilities for this purpose.
"The facilities are expected to test approx 60 batches of vaccines per month. The facilities are geared up to test existing Covid-19 vaccines and other newer Covid-19 vaccines as per demand of the nation. This will not only expedite the vaccine manufacture and supply but also be logistically convenient considering that both Pune and Hyderabad are the two vaccine manufacturing hubs," the statement said.
The Department of Biotechnology, under the Science & Technology Ministry, now has set up facilities in its autonomous research institutes, the NCCS, and the NIAB, for batch testing and quality control of vaccines.
Since the COVID-19 pandemic, Department of Biotechnology has been in the forefront contributing to various COVID-19 related activities including Vaccine Development, Diagnostics and testing, bio-banking and genomic surveillance, in addition to fundamental research and also building a strong ecosystem for translational research
DBT-NCCS and DBT-NIAB have been the pillars for many aspects of infectious disease related work in India and have contributed to advancement of cutting-edge research output in frontier areas of Biotechnology relevant to human health and disease.
With IANS Inputs
An appeal from Swarajya
At Swarajya, we rely on our readers' support through subscriptions to sustain our media platform. Unlike larger conglomerates, we are unable to relentlessly chase advertising money — our model is largely built on your patronage.
Your support has never been more crucial. We work tirelessly to deliver 10-15 high-quality articles daily, ensuring you receive insightful content from 7 AM to 10 PM.
If you believe India's story has to be articulated in a way it has never been done before without shrugging it off, become a patron (or) subscribe now for ₹̶2̶4̶0̶0̶ ₹1999 and get 12 print issues, unlimited digital access for 1 year, a special India that is Bharat T-shirt (Offer ends soon).
We are counting on you!